| Compound Information | SONAR Target prediction |
| Name: | DOXEPIN HYDROCHLORIDE |
| Unique Identifier: | SPE01500264 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 293.662 g/mol |
| X log p: | 19.313 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 12.47 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 3 |
| Canonical Smiles: | Cl.CN(C)CCC=C1c2ccccc2COc2ccccc21 |
| Source: | synthetic |
| Therapeutics: | antidepressant |
| Generic_name: | Doxepin |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449409 |
| Kegg_compound_id: | C06971 |
| Drugbank_id: | APRD00398 |
| Melting_point: | 184-186 oC |
| H2o_solubility: | 4.9 mg/L |
| Logp: | 4.189 |
| Cas_registry_number: | 1668-19-5 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C1668195&Index=0&Type=Mass&Large=on |
| Drug_category: | Anti-anxiety Agents; Antipruritics; Antidepressants; Norepinephrine-Reuptake
Inhibitors; Histamine Antagonists; ATC:N06AA12 |
| Indication: | For the treatment of psychoneurotic patients with depression and/or anxiety |
| Pharmacology: | Doxepin, a tricyclic antidepressant of the dibenzoxepin type, is used to treat
depression and anxiety and, topically, pruritus associated with eczema. Doxepin has
substantial anticholinergic and sedative effects. |
| Mechanism_of_action: | The mechanism of action of doxepin is not completely understood. It is thought that
Like amitriptyline, doxepin enhances the actions of norepinephrine and serotonin by
blocking their reuptake at the neuronal membrane. Doxepin may also act on histamine
H1-receptors, resulting in sedative effects, and beta-adrenergic
receptors. |
| Organisms_affected: | Humans and other mammals |
